Ash Jayagopal

Company: Opus Genetics

Job title: Chief Scientific & Development Officer

Seminars:

Analysis of Biomarker Approaches & Clinical Endpoints for Neovascular Retinal Disorders 1:01 pm

This workshop will focus on the critical role of biomarkers and clinical endpoints in the development of therapies for neovascular retinal disorders, including diabetic retinopathy (DR) and wet age-related macular degeneration (AMD). Participants will engage in discussions surrounding the complexities of endpoint selection, the advancements in imaging technologies, and the implications of emerging biomarkers for…Read more

day: Pre-Conference Day

Fireside Chat: Early Intervention vs. Monitoring in NPDR: Navigating the Controversy 4:00 pm

Debate the merits of early treatment versus monitoring in non-proliferative diabetic retinopathy (NPDR), considering the potential to alter disease progression and prevent vision-threatening events Examine the significant industry investment in early intervention strategies, such as Genentech’s port delivery systems, and their potential to reduce the incidence of diabetic macular edema (DME) and other complications Analyze…Read more

day: Day One